GDC-0449 in patients with advanced chondrosarcomas: A French sarcoma group/US and French national cancer institute single-arm phase ii collaborative study

Annals of Oncology

Volumn 24, Issue 11, 2013, Pages 2922-2926

  Italiano, A ^a   Le Cesne, A ^b   Bellera, C ^a,c   Piperno Neumann, S ^d   Duffaud, F ^e   Penel, N ^f   Cassier, P ^g   Domont, J ^b   Takebe, N ^h   Kind, M ^a   Coindre, J M ^a   Blay, J Y ^g   Bui, B ^a  

^a INSTITUT BERGONIÉ   (France)

^b INSTITUT GUSTAVE ROUSSY   (France)

^c CTD INCa   (France)

^d INSTITUT CURIE   (France)

^e TIMONE HOSPITAL   (France)

^f CENTRE OSCAR LAMBRET   (France)

^g CENTRE LÉON BÉRARD   (France)

^h NATIONAL CANCER INSTITUTE   (United States)

Author keywords

Chondrosarcoma; Gdc 0449; Hedgehog pathway; Treatment

Indexed keywords

SONIC HEDGEHOG PROTEIN; VISMODEGIB;

ABDOMINAL PAIN; ADULT; AGED; ALOPECIA; ARTICLE; CANCER GRADING; CHONDROSARCOMA; CLINICAL ARTICLE; DRUG EFFICACY; DRUG SAFETY; DRUG WITHDRAWAL; DYSGEUSIA; FATIGUE; FEMALE; FOLLOW UP; HUMAN; MALE; MULTICENTER STUDY; MULTIPLE CYCLE TREATMENT; MYALGIA; OVERALL SURVIVAL; PHASE 2 CLINICAL TRIAL; PRIORITY JOURNAL; PROGRESSION FREE SURVIVAL; SIDE EFFECT;

CHONDROSARCOMA; GDC-0449; HEDGEHOG PATHWAY; TREATMENT;

ADULT; AGED; AGED, 80 AND OVER; ANILIDES; CHONDROSARCOMA; DISEASE-FREE SURVIVAL; DRUG-RELATED SIDE EFFECTS AND ADVERSE REACTIONS; FEMALE; FRANCE; GENE EXPRESSION REGULATION, NEOPLASTIC; HEDGEHOG PROTEINS; HUMANS; MALE; MIDDLE AGED; PYRIDINES;

EID: 84887066721     PISSN: 09237534     EISSN: 15698041     Source Type: Journal    
DOI: 10.1093/annonc/mdt391     Document Type: Article

References (21)

1. Gelderblom H, Hogendoorn PC, Dijkstra SD et al. The clinical approach towards chondrosarcoma. Oncologist 2008; 13: 320-329.
2. Ng JM, Curran T. The Hedgehog's tale: developing strategies for targeting cancer. Nat Rev Cancer 2011; 11: 493-501.
3. Tiet TD, Hopyan S, Nadesan P et al. Constitutive Hedgehog signaling in chondrosarcoma up-regulates tumor cell proliferation. Am J Pathol 2006; 168: 321-330.
4. Campbell V, Puviindran Nadesan P, Wang Y et al. Direct targeting of the Hedgehog pathway in primary chondrosarcoma xenografts with the Smoothened inhibitor IPI-926. Cancer Res 2011; 71 (Suppl. 1): AM2011-LB-380.
5. Rudin CM. Vismedogib. Clin Cancer Res 2012; 18: 3218-3222.
6. Eisenhauer EA, Therasse P, Bogaerts J et al. New response evaluation criteria in solid tumours: revised RECIST guideline (version 1.1). Eur J Cancer 2009; 45: 228-247.
7. Ries LAG, Melbert D, Krapcho M et al. SEER Cancer Statistics Review, 1975- 2004. Bethesda, MD: National Cancer Institute 2007. http://seer.cancer.gov/csr/1975_2004/(2 January 2013, date last accessed).
8. Giuffrida AY, Burgueno JE, Koniaris LG et al. Chondrosarcoma in the United States (1973 to 2003): an analysis of 2890 cases from the SEER database. J Bone Joint Surg Am 2009; 91: 1063-1072.
9. Simon R. Optimal two-stage designs for phase II clinical trials. Control Clin Trials 1989; 10: 1-10.
10. Verweij J. Other endpoints in screening studies for soft tissue sarcomas. Oncologist 2008; 13(Suppl. 2): 27-31.
11. Penel N, Demetri GD, Blay JY et al. Growth modulation index as metric of clinical benefit assessment among advanced soft tissue sarcoma patients receiving trabectedin as a salvage therapy. Ann Oncol 2013; 24: 537-542.
12. Von Hoff DD. There are no bad anticancer agents, only bad clinical trial designs- Twenty-First Richard and Hinda Rosenthal Foundation Award Lecture. Clin Cancer Res 1998; 4: 1079-1086.
13. Mick R, Crowley JJ, Carroll RJ. Phase II clinical trial design for noncytotoxic anticancer agents for which time to disease progression is the primary endpoint. Control Clin Trials 2000; 21: 343-359.
14. van Oosterwijk JG, Herpers B, Meijer D et al. Restoration of chemosensitivity for doxorubicin and cisplatin in chondrosarcoma in vitro: BCL-2 family members cause chemoresistance. Ann Oncol 2012; 23: 1617-1626.
15. Italiano A, Mir O, Cioffi A et al. Advanced chondrosarcomas: role of chemotherapy and survival. Ann Oncol 2013; 24: 2916-2922.
16. Picci P, van Maldegem A, Palmerini E et al. Outcome of advanced inoperable central chondrosarcoma. CTOS Annual Meeting 2012, November 14-17, Prague, Czech Republic abstr. 55.
17. Xie J, Murone M, Luoh SM et al. Activating Smoothened mutations in sporadic basal-cell carcinoma. Nature 1998; 391: 90-92.
18. Wolter M, Reifenberger J, Sommer C et al. Mutations in the human homologue of the Drosophila segment polarity gene patched (PTCH) in sporadic basal cell carcinomas of the skin and primitive neuroectodermal tumors of the central nervous system. Cancer Res 1997; 57: 2581-2585.
19. LoRusso PM, Rudin CM, Reddy JC et al. Phase I trial of Hedgehog pathway inhibitor vismodegib (GDC-0449) in patients with refractory, locally advanced or metastatic solid tumors. Clin Cancer Res 2011; 17: 2502-2511.
20. Chen YJ, Kuo CD, Chen SH et al. Small-molecule synthetic compound norcantharidin reverses multi-drug resistance by regulating Sonic Hedgehog signaling in human breast cancer cells. PLoS One 2012; 7: e37006.
21. Kim DW, Kim KO, Shin MJ et al. siRNA-based targeting of antiapoptotic genes can reverse chemoresistance in P-glycoprotein expressing chondrosarcoma cells. Mol Cancer 2009; 8: 28.